Roche Canada Announces Purchase Agreement with the Government of Canada for ACTEMRA® IV (tocilizumab for injection) for Treatment of Adult Patients with COVID-19
MISSISSAUGA, ON, Dec. 1, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA IV (tocilizumab for injection) for adult patients hospitalized with COVID-19.
- MISSISSAUGA, ON, Dec. 1, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA IV (tocilizumab for injection) for adult patients hospitalized with COVID-19.
- Doses exceeding 800 mg per infusion are not recommended in patients with COVID-19.4
Based on the agreement to procure supply of ACTEMRA, the Government of Canada works with provincial and territorial partners to allocate the supply equitably across jurisdictions. - We're an innovator across major disease areas, including oncology, infectious diseases, diabetes, ophthalmology, and diseases of the central nervous system.
- For more information, please visit www.RocheCanada.com or follow Roche Canada on LinkedIn, or on Twitter @RocheCanada.